



NDA 211109/S-004

**APPROVAL LETTER**

Tetraphase Pharmaceuticals Inc  
Attention: Maria Gawryl, PhD  
Senior Vice President, Regulatory Affairs and Quality  
480 Arsenal Way, Suite 100  
Watertown, MA 02472

Dear Dr. Gawryl:

Please refer to your Supplemental New Drug Application (sNDA) dated and received February 7, 2020, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Xerava (eravacycline) for Injection, 50 mg.

This Prior Approval supplemental new drug application provides for the following changes:

1. Addition of a new strength of XERAVA (eravacycline) for injection containing 100 mg of eravacycline per vial.
  - The 100 mg/vial product will be manufactured at the (b) (4) with a (b) (4) batch size.
  - A new container closure will be used for the 100 mg/vial product, a 20-mm grey (b) (4) rubber (b) (4) stopper supplied by (b) (4).
  - New secondary packaging configuration for the 100 mg/vial product containing twelve single-dose vial cartons shrink-wrapped into a twelve-vial package.
  - Updated labeling to add the 100 mg/vial product.
2. Extension of the “in-use” shelf life for XERAVA diluted ready for infusion IV from 7 days to 10 days under refrigerated conditions for the existing 50 mg/vial product and the proposed 100 mg/vial product.
  - Updated labeling to extend the XERAVA diluted ready for infusion IV shelf life from 7 days to 10 days.

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the prescribing information) with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **CARTON AND IMMEDIATE CONTAINER LABELS**

Submit final printed carton and immediate container labels that are identical to enclosed carton and immediate container labels, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (May 2015, Revision 3)*. For administrative purposes, designate this submission “**Product Correspondence – Final Printed Carton and Container Labels for approved NDA 211109/S-004.**” Approval of this submission by FDA is not required before the labeling is used.

We remind you that you must comply with reporting requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Chinedu Ebonine, Regulatory Business Process Manager, at (240) 402 - 3448.

Sincerely,

*{See appended electronic signature page}*

David Lewis, Ph.D.  
Branch Chief, BII  
Division of Post-Marketing Activities I  
Office of Lifecycle Drug Products  
Office of Pharmaceutical Quality  
Center for Drug Evaluation and Research

Enclosure(s):

Content of Labeling  
Carton and Container Labeling



David  
Lewis

Digitally signed by David Lewis  
Date: 6/03/2020 04:37:35PM  
GUID: 508da72000029f287fa31e664741b577